CHC – The Cancer & Hematology Centers

SGN ALPV-001 (Seagen, Inc.)

Description:  A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors

Mechanism of Action:  antibody drug conjugate to ALPP (placental alkaline phosphatase) and ALPP2 (human alkaline phosphatase, placental like-2).  These are tumor antigens present on below cancers

Target Patient Population:  Ovarian, Endometrial, Non Small Cell Lung Cancer, Gastric, Cervical, Testicular cancers, Ovarian germ cell tumors

Study Design:  Drug is administered IV Day 1, 8 of a 21 day cycle.  Alternative schedules may be considered.